The insurance plan for North Carolina, NC, state employees was paying for 2,800 people to take weight-loss drugs in June 2021, but last year it paid for nearly 25,000 employees, costing the North Carolina State Health Plan $100M last year, Rebecca Robbins of The New York Times reports. In response to the increasing costs, the health plan’s governing board voted to end all coverage of medications for weight loss, including Novo Nordisk’s (NVO) Wegovy and Eli Lily’s (LLY) Zepbound.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Is NVO a Buy, Before Earnings?
- Suspected fake Ozempic linked to three cases of hypoglycemia, Reuters reports
- Guggenheim ups CymaBay price target to $28, sees M&A potential
- Zealand Pharma believes it can compete in weight-loss drug market, FT says
- Novo Nordisk initiated with an Overweight at Morgan Stanley
Questions or Comments about the article? Write to editor@tipranks.com